For additional information, please contact the BMS oncology clinical trial information
service at 855-216-0126 or email MyCancerStudyConnect@emergingmed.com. Please visit
www.BMSStudyConnect.com for more information on clinical trial participation

Inclusion Criteria:

- Subjects with histological confirmation of RCC

- Advanced or metastatic disease

- Measurable disease as defined by RECIST 1.1 criteria

- Karnofsky Performance Status (KPS) ≥80%

- Available tumor tissue (archival or recent acquisition)

Exclusion Criteria:

- Active central nervous system (CNS) metastases

- Active or history of autoimmune disease

- Ongoing symptomatic cardiac dysrhythmias or uncontrolled atrial fibrillation

- History of cerebrovascular accident including transient ischemic attack within the
past 12 months

- History of pulmonary embolism or deep vein thrombosis (DVT) within the past 6 months

- Chronic systemic steroids (>10 mg/day Prednisone equivalents) or any other
immunosuppressive agents

- White blood cell (WBC) <2,000/mm3

- Neutrophiles <1,500/mm3

- Platelets <100,000/mm3

- Aspartate aminotransferase (AST) or Alanine aminotransferase (ALT) >3x upper limit of
normal (ULN)

- Total Bilirubin >1.5x ULN (except subjects with Gilbert syndrome, total bilirubin
<3.0 mg/dL)

- Cardiac ejection fraction
- Serum creatinine >1.5x ULN or creatinine clearance <40 mL/min (Cockroft-Gault
formula)

Exclusion Criteria for Arm S and Arm P only:

- For dose escalation cohorts - subjects who received prior Sunitinib or Pazopanib and
required permanent discontinuation due to toxicity or required dose reduction or
delay during the first 12 weeks of therapy due to toxicity, or received both prior
Sunitinib and Pazopanib

- Poorly controlled hypertension

- Active bleeding or bleeding susceptibility